Summary of all simulated surveillance strategies. by Callum Shaw (15628313)

Model of the observed species density. by Stijn Bruneel (8113409)

Sampling design of the study. by Stijn Bruneel (8113409)

Model of the observed Shannon diversity. by Stijn Bruneel (8113409)

Lack of HP1a or POF shifts the enrichment pattern of RNA pol II on chromosome 4. by Nicole C. Riddle (134424)

“…In both HP1a and POF mutants, the RNA pol II enrichment decreases significantly only in the gene body. …”

Results of the original ABC fitting. by Callum Shaw (15628313)

Visualisation of quadrants for the comparison of each IAA adequacy relative to protein adequacy. by Bi Xue Patricia Soh (21100364)

Regression analysis describing relationship between TID-adjusted total protein (g) and each TID-adjusted IAA consumption (g). by Bi Xue Patricia Soh (21100364)

Annual territory-wide antigen prevalence for school-based and workplace-based interventions. by Callum Shaw (15628313)

Early CA-DNA accumulation prior to and following ART initiation. by Brandon F. Keele (7450001)

Early CA-RNA accumulation prior to and following ART initiation. by Brandon F. Keele (7450001)

CD8 depletion fails to cause rebound in non-rebounding off-ART RMs. by Brandon F. Keele (7450001)

Consistent barcode distribution across multiple tissues during primary infection. by Brandon F. Keele (7450001)

Total pVL measurements from challenge to treatment interruption. by Brandon F. Keele (7450001)

CA-RNA and CA-DNA viral load measurements from PBMC, peripheral LNMCs, DUO and BM from 3, 70, and 250 dpi. by Brandon F. Keele (7450001)

Early pre- and post-ART plasma viral load dynamics of individual RMs. by Brandon F. Keele (7450001)

Delay in first phase viral decay kinetics when ART is started pre-peak. by Brandon F. Keele (7450001)

Barcode comparisons pre-ART versus post-ART rebound. by Brandon F. Keele (7450001)

Viral measurements do not predict off-ART rebound in d4 and d5 ART RMs. by Brandon F. Keele (7450001)

Intranasal NIC-hLYS is efficacious in vivo against MERS-CoV. by Ashlee D. Brunaugh (4263472)

“…<p>The efficacy of NIC-hLYS particles was assessed in a lethal MERS-CoV infection model (A). Once daily intranasal administration of NIC-hLYS particles suspended in 0.45% sodium chloride resulted in 43% survival in a lethal MERS-CoV infection (B) and produced a statistically significant decrease in lung viral titer at the highest dose tested (C). …”